Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aplidin in Myelofibrosis
NCT01149681Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Jul 2010
- Primary completion
- Feb 2011
- Modality
- Cyclic Peptides, Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of plitidepsin in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by PharmaMar. Primary endpoint: Objective Response Rate up to 1 year. Started Jul 2010; status: completed.
02
Drugs
plitidepsin
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT01149681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01149681.